Overview

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Status:
Recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The goal of this phase 2 trial is to test the safety and efficacy of azacitidine when given together with PD-1 therapy in treating patients with relapsed/refractory classic Hodgkin lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Navy General Hospital, Beijing
Treatments:
Azacitidine